News

In his previous position, Dr Lanthaler served as CFO of Intercell in Vienna, Austria, a biopharmaceutical company. In this role, Dr Lanthaler was also responsible for business development

Proceeds will be used to support future growth initiatives, including product acquisitions. As part of the transaction, Victory announced that Scott Barry, Essex Partner, has joined its board

Although preliminary data, needing further analysis, show activity of Bevasiranib when used adjunctively with Genentech’s Lucentis, review of the data by the Independent Data Monitoring Committee indicated that

Most recently, Mr Lonergan served as vice president of sales, marketing, and business development for Ibis Biosciences. Prior to Ibis, Mr Lonergan held similar executive positions at 454

According to the company, the interim results indicate that sequential treatment of plaque psoriasis with Clobex spray followed by Vectical ointment is effective in managing plaque psoriasis over

In the initial stage of the program, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed

CV Therapeutics, a biopharmaceutical company, has announced that CVT-3619, a novel oral compound for potential treatment of cardiometabolic diseases, was well tolerated with no serious adverse events and

The company reported revenues of $147.2 million for the first quarter ended January 31, 2009, a decrease of 10.4%, compared to $164.2 million for the corresponding period of

In his new role, Mr Kandera will be responsible for the global finance function and investor relations of Intercell. Mr Kandera is currently CFO of Intercell’s US subsidiary